Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Merck & Co., Inc.
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
European Commission Expands Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents
October 24, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation
October 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
October 18, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines
October 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
October 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
October 06, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
September 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
September 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Animal Health Completes Minority Investment in LeeO Precision Farming
September 27, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
September 27, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Animal Health to Acquire Vence
September 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
September 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
September 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
September 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)
September 11, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
September 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials
September 09, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Reports Strong Progress in ESG Focus Areas
August 30, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
August 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
August 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy
August 23, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
August 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
August 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
August 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
August 03, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
August 03, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Second-Quarter 2022 Financial Results
July 28, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Fourth-Quarter 2022 Dividend
July 26, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
July 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.